Table 5.
Network meta-analysis including KEYNOTE-355 patients assigned to nab-paclitaxel or paclitaxel combined.
| Overall survival | |||||||
|---|---|---|---|---|---|---|---|
| Nab-paclitaxel/paclitaxel | 1.30 (0.97, 1.75) | 1.20 (0.95, 1.51) | 0.66 (0.41, 1.06) | 0.56 (0.37, 0.84) | 0.94 (0.61, 1.43) | 1.62 (1.05, 2.52) | 1.85 (1.23, 2.79) |
| 0.77 (0.57, 1.04) | Atezolizumab + nab-paclitaxel | 0.92 (0.63, 1.35) | 0.51 (0.29, 0.89) | 0.43 (0.26, 0.71) | 0.72 (0.43, 1.21) | 1.25 (0.74, 2.12) | 1.42 (0.86, 2.37) |
| 0.83 (0.66, 1.05) | 1.08 (0.74, 1.58) | Bevacizumab + paclitaxel | 0.55 (0.32, 0.94) | 0.47 (0.29, 0.74) | 0.78 (0.55, 1.11) | 1.35 (0.93, 1.96) | 1.54 (0.96, 2.47) |
| 1.52 (0.94, 2.45) | 1.97 (1.12, 3.47) | 1.82 (1.07, 3.10) | Carboplatin | 0.85 (0.66, 1.10) | 1.42 (0.75, 2.69) | 2.46 (1.29, 4.71) | 2.81 (1.49, 5.26) |
| 1.79 (1.19, 2.67) | 2.32 (1.40, 3.84) | 2.14 (1.34, 3.42) | 1.18 (0.91, 1.52) | Docetaxel | 1.68 (0.93, 3.00) | 2.90 (1.59, 5.25) | 3.31 (1.86, 5.87) |
| 1.07 (0.70, 1.63) | 1.38 (0.83, 2.31) | 1.28 (0.90, 1.82) | 0.70 (0.37, 1.33) | 0.60 (0.33, 1.07) | Ixabepilone + bevacizumab | 1.73 (1.20, 2.48) | 1.97 (1.09, 3.55) |
| 0.62 (0.40, 0.95) | 0.80 (0.47, 1.36) | 0.74 (0.51, 1.07) | 0.41 (0.21, 0.78) | 0.35 (0.19, 0.63) | 0.58 (0.40, 0.83) | Nab-paclitaxel + bevacizumab | 1.14 (0.62, 2.08) |
| 0.54 (0.36, 0.82) | 0.70 (0.42, 1.17) | 0.65 (0.40, 1.04) | 0.36 (0.19, 0.67) | 0.30 (0.17, 0.54) | 0.51 (0.28, 0.92) | 0.88 (0.48, 1.60) | Pembrolizumab + nab-paclitaxel/paclitaxel |
| Progression-free survival | |||||||
|---|---|---|---|---|---|---|---|
| Nab-paclitaxel/paclitaxel | 1.41 (1.10, 1.80) | 1.81 (1.41, 2.33) | 1.15 (0.73, 1.81) | 1.20 (0.80, 1.79) | 1.30 (0.86, 2.00) | 2.30 (1.48, 3.55) | 1.72 (1.17, 2.55) |
| 0.71 (0.56, 0.91) | Atezolizumab + nab-paclitaxel | 1.29 (0.91, 1.83) | 0.82 (0.49, 1.37) | 0.85 (0.53, 1.36) | 0.93 (0.57, 1.51) | 1.63 (0.99, 2.68) | 1.22 (0.77, 1.94) |
| 0.55 (0.43, 0.71) | 0.78 (0.55, 1.10) | Bevacizumab + paclitaxel | 0.64 (0.38, 1.07) | 0.66 (0.41, 1.06) | 0.72 (0.51, 1.01) | 1.27 (0.89, 1.81) | 0.95 (0.60, 1.51) |
| 0.87 (0.55, 1.36) | 1.22 (0.73, 2.04) | 1.57 (0.94, 2.63) | Carboplatin | 1.04 (0.84, 1.28) | 1.13 (0.61, 2.11) | 1.99 (1.06, 3.74) | 1.50 (0.82, 2.72) |
| 0.83 (0.56, 1.25) | 1.18 (0.73, 1.87) | 1.51 (0.94, 2.43) | 0.96 (0.78, 1.19) | Docetaxel | 1.09 (0.61, 1.95) | 1.91 (1.06, 3.46) | 1.44 (0.82, 2.51) |
| 0.77 (0.50, 1.17) | 1.08 (0.66, 1.76) | 1.39 (0.99, 1.96) | 0.88 (0.47, 1.64) | 0.92 (0.51, 1.65) | Ixabepilone + bevacizumab | 1.76 (1.24, 2.49) | 1.32 (0.74, 2.35) |
| 0.44 (0.28, 0.67) | 0.61 (0.37, 1.01) | 0.79 (0.55, 1.13) | 0.50 (0.27, 0.94) | 0.52 (0.29, 0.95) | 0.57 (0.40, 0.81) | Bevacizumab + nab-paclitaxel | 0.75 (0.42, 1.35) |
| 0.58 (0.39, 0.86) | 0.82 (0.51, 1.29) | 1.05 (0.66, 1.67) | 0.67 (0.37, 1.22) | 0.70 (0.40, 1.22) | 0.76 (0.43, 1.35) | 1.33 (0.74, 2.39) | Pembrolizumab + nab-paclitaxel/paclitaxel |
Each cell represents the comparison (HR and 95% CrI) of the row treatment vs the column treatment. All bolded values are statistically meaningful at the 0.05 level. Overall survival: deviance information criterion: 13.37; deviance: 6.38. Progression-free survival: Deviance information criterion: 13.67; deviance: 6.66.
HR: Hazard ratio; CrI: Credible interval.